BioCentury | Mar 15, 2021

Versant-built gene editing company Graphite speeds clinical plans with crossover-laden $150M series B

Crossover investors have poured into Graphite’s $150 million series B round six months after the gene therapy company’s launch based on technology out of the Stanford lab of Matthew Porteus, setting it on a quick path...
BioCentury | Mar 6, 2021
Politics, Policy & Law

PTAB expected to get a Supreme pass

Whether the Supreme Court finds the Patent Trial and Appeal Board’s current structure to be unconstitutional may be down to a coin flip. Regardless of the outcome, it is likely that the inter partes...
BioCentury | Mar 5, 2021
Translation in Brief

A stem cell therapy for brain metastases in breast cancer; plus a nanoparticle gene editing delivery tech and more

A team led by Khalid Shah from Harvard Medical School engineered allogeneic stem cells with an anti-EGFR camelid antibody fused to a death receptor ligand. Published in Science Advances, the therapy induced apoptosis of cancer...
BioCentury | Feb 11, 2021
Emerging Company Profile

BigHat: AI for antibody optimization beyond target engagement

BigHat, which raised $19 million in an A round led by Andreessen Horowitz on Wednesday, is marrying lab assays with machine learning to optimize antibodies for properties beyond target engagement.  The San Carlos, Calif.-based company’s three...
BioCentury | Feb 10, 2021

CRISPR play Caribou broadens therapeutics reach with AbbVie deal to develop allogeneic CAR Ts

After giving up rights to CRISPR-Cas9 for most therapeutic applications years ago, Jennifer Doudna-founded Caribou is now teaming up with AbbVie to use a different CRISPR enzyme to create allogeneic CAR...
BioCentury | Jan 30, 2021
Distillery Therapeutics

CRISPR base editing to treat progeria

DISEASE CATEGORY: Other INDICATION: Progeria A team led NIH Director Francis Collins, CRISPR pioneer David Liu, and Vanderbilt University’s Jonathan Brown showed that a CRISPR adenine base editor could treat Hutchinson-Gilford progeria syndrome, which is...
BioCentury | Jan 15, 2021
Politics, Policy & Law

New relevance, old guard: Biden throws weight behind science, puts Lander in Cabinet, keeps Collins at NIH

President-elect Joe Biden is raising the profile of science in his administration by elevating the role of presidential science advisor to a Cabinet position, naming the Broad Institute’s Eric Lander to the post, and nominating...
BioCentury | Jan 12, 2021

Jan. 11 Quick Takes: Inmagene gains options to four Chi-Med immunology programs; plus Zai-Turning Point, Mirati-Resolution, GSK-Eligo, Biogen-Apple, Adaptive-AZ and more

Chi-Med, Inmagene partner on immunological indicationsHutchison China MediTech Ltd. (NASDAQ:HCM; LSE:HCM) granted Inmagene Biopharmaceuticals Co. Ltd. exclusive options to four immunological diseases programs for up to $95 million in development milestones, $135 million in commercial...
BioCentury | Jan 9, 2021
Translation in Brief

Fusing camelid antibodies to toxin derivatives to treat botulism; plus BioNTech applies platform to multiple sclerosis, a molecule that stops axon degeneration and more

Antibody-toxin fusions as botulism treatmentTwo groups reported in Science Translational Medicine taking advantage of atoxic botulinum neurotoxin (BoNT) derivatives to deliver single-domain antibodies into neurons to treat botulism. A Boston Children’s Hospital group found that intramuscular...
BioCentury | Dec 17, 2020
Emerging Company Profile

Exo: expanding the universe of druggable enzymes

Exo debuted Wednesday with $25 million in series A funding to broaden the universe of druggable enzymes and improve drug selectivity by developing small molecules against non-catalytic, non-allosteric sites. Exo Therapeutic Inc., which is backed by...
Items per page:
1 - 10 of 1000